甲状腺功能亢进症和眼眶疾病的严重程度不会改变格雷夫斯眼病患者的中央角膜厚度。
Hyperthyroidism and severity of orbital disease do not change the central corneal thickness in Graves' ophthalmopathy.
作者信息
Konuk O, Aktas Z, Aksoy S, Onol M, Unal M
机构信息
Department of Ophthalmology, Gazi University School of Medicine, Ankara, Turkey.
出版信息
Eur J Ophthalmol. 2008 Jan-Feb;18(1):125-7.
PURPOSE
To investigate whether the central corneal thickness (CCT) shows alterations in Graves disease and Graves ophthalmopathy (GO) cases according to the disease severity and hormonal status of the patients.
METHODS
A total of 150 patients (62 male, 88 female) with Graves disease and 32 control subjects (11 male, 21 female) were included in the study. The patients were divided into six groups according to the severity of orbital involvement and thyroid hormone status. Best-corrected visual acuity, pupillary responses, color vision, biomicroscopy, CCT, intraocular pressure, and funduscopy were performed, and proptosis was measured with Hertel exophthalmometry in all patients.
RESULTS
CCT values of patients with Graves disease and patients with GO with hyperthyroid or euthyroid hormonal status showed no statistical difference among themselves and versus control subjects (p>0.05).
CONCLUSIONS
Hyperthyroidism or severity of orbital disease does not affect the CCT.
目的
根据患者的疾病严重程度和激素状态，研究格雷夫斯病和格雷夫斯眼病（GO）患者的中央角膜厚度（CCT）是否出现改变。
方法
本研究共纳入150例格雷夫斯病患者（男性62例，女性88例）和32例对照者（男性11例，女性21例）。根据眼眶受累程度和甲状腺激素状态将患者分为六组。对所有患者进行最佳矫正视力、瞳孔反应、色觉、生物显微镜检查、CCT、眼压和眼底检查，并用Hertel眼球突出计测量眼球突出度。
结果
格雷夫斯病患者以及甲状腺功能亢进或甲状腺功能正常的GO患者的CCT值在彼此之间以及与对照者之间均无统计学差异（p>0.05）。
结论
甲状腺功能亢进或眼眶疾病的严重程度不影响CCT。
Zotero 插件